Evommune

Evommune EBIT per Share

The EBIT per Share of Evommune (EVMN) as of Oct 28, 2026 is -2.57 USD. In the previous year, EBIT per Share was -2.33 USD — a change of 10.48% (lower).

EBIT per Share

-2.57USD

YoY

10.48%

Last updated:

EBIT per Share of Evommune is 2025 -2.57 USD. EBIT per Share of Evommune was 2024 -2.33 USD. It decreases by 10.48% lower compared to the previous year.

The Evommune EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-1.26 USD
Jan 1, 2024
-2.33 USD
Jan 1, 2025
-2.57 USD
Jan 1, 2026 (e)
-0.13 USD
Jan 1, 2027 (e)
-0.04 USD
Jan 1, 2028 (e)
-0.06 USD
Jan 1, 2029 (e)
-0.20 USD
Jan 1, 2030 (e)
-1.56 USD
The Evommune EBIT per Share history
YEAREBIT per ShareYoY
est-1.56USD+685.20%
est-0.20USD+212.50%
est-0.06USD+60.00%
est-0.04USD-69.70%
est-0.13USD-94.91%
-2.57USD+10.48%
-2.33USD+84.97%
-1.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

EBIT per Share of Evommune is -2.57 USD in 2025.

EBIT per Share of Evommune changed from -2.33 USD to -2.57 USD, representing a 10.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Evommune since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Evommune

All Key Metrics — Evommune